2 results
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Not approvedWill not start
The HemaTrate Blood Filtration System is commercially available and indicated for the rapid preparation of a TNC concentrate for use in human cell therapy applications. This study is designed to obtain the data needed to support a new, specific…